Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To define in human preclinical systolic dysfunction (PSD) the actions of chronic administration of SQ BNP [nesiritide] on the left ventricular, renal and humoral function and on the integrated response to acute sodium loading.

Trial Profile

To define in human preclinical systolic dysfunction (PSD) the actions of chronic administration of SQ BNP [nesiritide] on the left ventricular, renal and humoral function and on the integrated response to acute sodium loading.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2014

At a glance

  • Drugs Nesiritide (Primary)
  • Indications Heart failure
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 Mar 2014 Primary endpoint and the number of arms (1 to 2) has been changed as reported by ClinicalTrials.gov record.
    • 20 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top